> Details

Fisher, Michael J; Liu, Grant T; Ferner, Rosalie E; Gutmann, David H; Listernick, Robert; de Blank, Peter; Zeid, Janice; Ullrich, Nicole J; Heidary, Gena; Bornhorst, Miriam; Stasheff, Steven F; Rosser, Tena; Borchert, Mark; Ardern-Holmes, Simone; Flaherty, Maree; Hummel, Trent R; Motley, W Walker; Bielamowicz, Kevin; Phillips, Paul H; Bouffet, Eric; Reginald, Arun; Wolf, David S; Peragallo, Jason; Van Mater, David; [...]

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
  • Contributor: Fisher, Michael J; Liu, Grant T; Ferner, Rosalie E; Gutmann, David H; Listernick, Robert; de Blank, Peter; Zeid, Janice; Ullrich, Nicole J; Heidary, Gena; Bornhorst, Miriam; Stasheff, Steven F; Rosser, Tena; Borchert, Mark; Ardern-Holmes, Simone; Flaherty, Maree; Hummel, Trent R; Motley, W Walker; Bielamowicz, Kevin; Phillips, Paul H; Bouffet, Eric; Reginald, Arun; Wolf, David S; Peragallo, Jason; Van Mater, David; [...]
  • Published: Oxford University Press (OUP), 2020
  • Published in: Neuro-Oncology, 22 (2020) Supplement_3, Seite iii419-iii419
  • Language: English
  • DOI: 10.1093/neuonc/noaa222.613
  • ISSN: 1522-8517; 1523-5866
  • Origination:
  • Footnote:
  • Description: Abstract INTRODUCTION Because treatment and clinical management decisions for children with NF1-OPG remain challenging, we sought to establish evidence-based guidelines. We prospectively enrolled children with newly-diagnosed NF1-OPGs, and gathered standardized clinical neuro-oncology and ophthalmology assessments. METHODS Only children with NF1 and newly diagnosed OPGs, confirmed by central review, were eligible. Indications for obtaining the initial MRI, as well as factors associated with the decision to treat with chemotherapy or observe without treatment, were obtained. Quantitative visual acuity (VA), other ophthalmic features, and imaging were captured at standard time points. Goal enrollment is 250 subjects. RESULTS One-hundred thirty-three children (52% female) from 20 institutions met inclusion criteria, and were included in this preliminary analysis. Eighty-six percent of subjects were able to perform quantitative VA testing at enrollment. The most common reasons for the diagnostic MRI included screening related to NF1 diagnosis (36.8%), ophthalmologic concerns (29.3%), and non-ophthalmologic concerns (24.8%), such as headache. To date, twenty subjects have initiated treatment with chemotherapy, twelve (9%) at the time of the initial OPG diagnosis. Median age at OPG diagnosis was 3.1 years. Age and sex distribution were similar in subjects immediately entering the observation and treatment arms (median age 3.0 versus 3.5 years, respectively). CONCLUSION Most children with NF1-OPGs are observed at time of their initial OPG diagnosis, rather than treated. Importantly, a large proportion of children are able to complete quantitative VA testing at enrollment. Once enrollment is complete, these data will help to establish evidence-based guidelines for clinical management of NF1-OPGs.
  • Access State: Open Access